Type 1 diabetes

Performance of Celiac Serologic Markers and Follow-Up Adherence in Children with Type 1 Diabetes and Comorbid Celiac Disease

Horm Res PaediatrPublished Retrospective cohort study

Authors' conclusion

TTG IgA ≥3.6 times ULN or positive EMA is recommended to proceed with CeD confirmation. In cases of mild TTG IgA positivity, EMA can guide CeD confirmation given its high negative predictive value.

Study context

Population
Children (≤18 years) diagnosed with T1D between 2000 and 2021, screened for celiac disease (CeD) after T1D diagnosis; single centre591 screened
Participants
734 children
Exposure
T1D+CeD vs CeD-only
Outcome
Celiac serology diagnostic performance (TTG IgA cutoff by AUC-ROC) and CeD follow-up rates
Methodological detailssingle-centre, matched controls (age and gender at tissue transglutaminase (TTG) IgA positivity)
  • Single-centre
  • Matched controls (age and gender at TTG IgA positivity)

Main finding

As reported in the abstract

TTG IgA ≥3.62 times ULN for biopsy-confirmed CeD vs no CeD
GroupSensitivitySpecificityPPVNPV
TTG IgA ≥3.62 times upper limit of normal (ULN)90%92%93%89%
Endomysial antibody (EMA)100%75%84%100%

Sensitivity

TTG IgA ≥3.62 times upper limit of normal (ULN)90%
Endomysial antibody (EMA)100%

Specificity

TTG IgA ≥3.62 times upper limit of normal (ULN)92%
Endomysial antibody (EMA)75%

PPV

TTG IgA ≥3.62 times upper limit of normal (ULN)93%
Endomysial antibody (EMA)84%

NPV

TTG IgA ≥3.62 times upper limit of normal (ULN)89%
Endomysial antibody (EMA)100%
Positive TTG IgA among screened T1D
70 (11.8%)
Confirmed CeD among TTG IgA positive
43 (61.4%)

Observational data: associations, not effects.

Further findings

Time to TTG IgA normalization · longer with T1D+CeD

P < 0.001

Pediatric gastroenterology CeD follow-up rate · lower with T1D+CeD

P < 0.001

Original publication

Performance of Celiac Serologic Markers and Follow-Up Adherence in Children with Type 1 Diabetes and Comorbid Celiac Disease. Horm Res Paediatr. Published 7 January 2026. doi:10.1159/000550313

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.